BTNX Inc. is a Canadian-based manufacturer of rapid diagnostic tests, offering over 100 lateral flow and digital point-of-care solutions across a wide range of clinical applications. BTNX’s products include tests for infectious diseases (e.g., COVID-19, dengue, HIV), chronic conditions (e.g., cardiac markers, cancer), pregnancy and fertility, drug screening, and urinalysis. Many of BTNX’s products are licensed by major global regulatory bodies including the US FDA, Health Canada, and more. BTNX’s clients include hospitals, clinics, labs, public health agencies, and distributors in more than 70 countries. With ISO 13485-certified manufacturing and a focus on innovation, they deliver reliable, accessible diagnostics that support timely decision-making in high-volume and decentralized healthcare environments.
Beyond the point of care, BTNX is an innovator in rapid detection tests for drugs including fentanyl, xylazine and date rape drugs like GHB – these tests are ideal for overdose prevention, law enforcement, and nightlife safety